Show simple item record

dc.contributor.authorGimenez-Sanchez, Alicia
dc.contributor.authorMorales-Molina, Álvaro 
dc.contributor.authorRodriguez-Milla, Miguel A 
dc.contributor.authorPerisé-Barrios, Ana Judith 
dc.contributor.authorGarcia-Castro, Javier 
dc.date.accessioned2020-07-27T20:18:31Z
dc.date.available2020-07-27T20:18:31Z
dc.date.issued2020-07-16
dc.identifier.citationCancers (Basel) . 2020 Jul 16;12(7):E1920.es_ES
dc.identifier.issn2072-6694es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10846
dc.description.abstractOncolytic virotherapy uses viruses designed to selectively replicate in cancer cells. An alternative to intratumoral administration is to use mesenchymal stem cells (MSCs) to transport the oncolytic viruses to the tumor site. Following this strategy, our group has already applied this treatment to children and adults in a human clinical trial and a veterinary trial, with good clinical responses and excellent safety profiles. However, the development of immunocompetent cancer mouse models is still necessary for the study and improvement of oncolytic viroimmunotherapies. Here we have studied the antitumor efficacy, immune response, and mechanism of action of a complete murine version of our cellular virotherapy in mouse models of renal adenocarcinoma and melanoma. We used mouse MSCs infected with the mouse oncolytic adenovirus dlE102 (OAd-MSCs). In both models, treatment with OAd-MSCs significantly reduced tumor volumes by 50% and induced a pro-inflammatory tumor microenvironment. Furthermore, treated mice harboring renal adenocarcinoma and melanoma tumors presented increased infiltration of tumor-associated macrophages (TAMs), natural killer cells, and tumor-infiltrating lymphocytes (TILs). Treated mice also presented lower percentage of TILs expressing programmed cell death protein 1 (PD-1)-the major regulator of T cell exhaustion. In conclusion, treatment with OAd-MSCs significantly reduced tumor volume and induced changes in tumor-infiltrating populations of melanoma and renal cancer.es_ES
dc.description.sponsorshipPI14CIII/00005/Ministerio de Economía y Competitividad PI17CIII/00013/Ministerio de Economía y Competitividad P2017/BMD-3692/Consejería de Educación, Juventud y Deporte of Comunidad de Madrid General grant/Fundación Oncohematología Infantil General grant/AFANIONes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectoncolytic viruses_ES
dc.subjectadenoviruses_ES
dc.subjectMSCses_ES
dc.subjectimmunotherapyes_ES
dc.subjectCelyvires_ES
dc.subjectTILses_ES
dc.subjectT cellses_ES
dc.subjectPD-1es_ES
dc.subjectrenalcanceres_ES
dc.subjectmelanomaes_ES
dc.titleCellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32708639es_ES
dc.format.volume12es_ES
dc.format.number7es_ES
dc.format.page1920es_ES
dc.identifier.doi10.3390/cancers12071920es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderComunidad de Madrides_ES
dc.contributor.funderFundacióes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2072-6694es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/cancers12071920es_ES
dc.identifier.journalCancerses_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14CIII/00005es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17CIII/00013es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/P2017/BMD-3692es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional